Baqain Zaid H, Sawair Faleh A, Tamimi Zaid, Bsoul Nazzal, Al Edwan Ghazi, Almasad Jamal K, Abbadi Abdalla A
Department of Oral and Maxillofacial Surgery, Oral Medicine and Periodontology, Faculty of Dentistry, University of Jordan, Amman, Jordan.
Ann R Coll Surg Engl. 2010 Sep;92(6):489-94. doi: 10.1308/003588410X12699663903395. Epub 2010 Jun 1.
We describe our experience with oncology patients on a frequent dosing schedule of intravenous (i.v.) bisphosphonates at the Jordan University Hospital (JUH).
Patients treated by i.v. bisphosphonates in the medical oncology unit at the JUH were examined for bisphosphonate-related osteonecrosis of the jaws (BRONJ). Diagnosis was made according to the guidelines of the American Association of Oral and Maxillofacial Surgeons (AAOMS) original position paper.
Of the 41 patients, four developed BRONJ, two in maxilla, one in mandible and one bimaxillary. Patients with BRONJ were older; mean age was 69.3 +/- 3.1 years compared to 62.8 +/- 12.5 years (P = 0.022). Dental co-morbidities were more commonly present in patients with the disease (P = 0.038). Patients who developed BRONJ were on treatment for a longer duration of time; the mean duration of treatment was 23.5 +/- 8.4 months compared to 11.9 +/- 13.4 months (P = 0.10).
The results of this case series demonstrated that age and poor oral health status are significant risk factors of BRONJ for oncology patients on long-term frequent dosing schedule of i.v. bisphosphonates.
我们描述了约旦大学医院（JUH）对肿瘤患者采用静脉注射双膦酸盐频繁给药方案的经验。
对在JUH医学肿瘤科接受静脉注射双膦酸盐治疗的患者进行颌骨双膦酸盐相关骨坏死（BRONJ）检查。诊断依据美国口腔颌面外科医师协会（AAOMS）原始立场文件的指南进行。
41例患者中，4例发生BRONJ，2例在上颌，1例在下颌，1例为双颌。发生BRONJ的患者年龄较大；平均年龄为69.3±3.1岁，而未发生者为62.8±12.5岁（P = 0.022）。合并口腔疾病在患病患者中更常见（P = 0.038）。发生BRONJ的患者治疗时间更长；平均治疗时间为23.5±8.4个月，而未发生者为11.9±13.4个月（P = 0.10）。
该病例系列结果表明，年龄和口腔健康状况差是接受长期频繁静脉注射双膦酸盐给药方案的肿瘤患者发生BRONJ的重要危险因素。
